Literature DB >> 25451692

Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.

Hui Zhang1, Lei Yan1, Yun Bai1, Chunyan Li1, Qiufen Guo1, Chong Wang2, Xingbo Zhao1, Mingjiang Li3.   

Abstract

OBJECTIVE: We previously found that Dual-specificity phosphatase 6 (Dusp6) over-expression enhanced the growth-promoting effect of estrogen in endometrial adenocarcinoma cells. The aim of this study was to explore the correlation of Dusp6 expression with progestin sensitivity in atypical endometrial hyperplasia (AEH) and earlier endometrial carcinomas (EC).
METHODS: Using immunohistochemistry study, we analyzed the expression of Dusp6 protein in AEH.
RESULTS: We found that progestin treatment was effective in 89% of AEH and 50% of EC. Before treatment, Dusp6 expression was significantly higher in progestin-sensitive AEH groups compared with progestin-resistant groups. After treatment, Dusp6 expression was significantly upregulated in progestin-sensitive groups, but not in progestin-resistant groups. Moreover, a high-dose of Dusp6 transfection significantly enhanced progestin-induced growth-inhibition in Ishikawa cells.
CONCLUSIONS: Dusp6 could be a predicting marker for deciding the effectiveness of progestin therapy in AEH.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atypical endometrial hyperplasia; Dusp6; Progesterone resistance; Progesterone sensitivity

Mesh:

Substances:

Year:  2014        PMID: 25451692     DOI: 10.1016/j.ygyno.2014.11.008

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

1.  Dual-specificity Phosphatase 1 Deficiency Induces Endometrioid Adenocarcinoma Progression via Activation of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Pathway.

Authors:  Yuan Yang; Jing-Yi Zhou; Li-Jun Zhao; Bao-Rong Gao; Xiao-Ping Wan; Jian-Liu Wang
Journal:  Chin Med J (Engl)       Date:  2016-05-20       Impact factor: 2.628

2.  Comprehensive bioinformatics analysis of acquired progesterone resistance in endometrial cancer cell line.

Authors:  Wenzhi Li; Shufen Wang; Chunping Qiu; Zhiming Liu; Qing Zhou; Deshui Kong; Xiaohong Ma; Jie Jiang
Journal:  J Transl Med       Date:  2019-02-27       Impact factor: 5.531

3.  Dusp6 inhibits epithelial-mesenchymal transition in endometrial adenocarcinoma via ERK signaling pathway.

Authors:  Ming-Jun Fan; Shu-Mei Liang; Peng-Juan He; Xing-Bo Zhao; Ming-Jiang Li; Feng Geng
Journal:  Radiol Oncol       Date:  2019-09-24       Impact factor: 2.991

4.  Identification of potential models for predicting progestin insensitivity in patients with endometrial atypical hyperplasia and endometrioid endometrial cancer based on ATAC-Seq and RNA-Seq integrated analysis.

Authors:  Jia-Li Hu; Gulinazi Yierfulati; Lu-Lu Wang; Bing-Yi Yang; Qiao-Ying Lv; Xiao-Jun Chen
Journal:  Front Genet       Date:  2022-08-26       Impact factor: 4.772

Review 5.  Fertility-Sparing Approach in Patients with Endometrioid Endometrial Cancer Grade 2 Stage IA (FIGO): A Qualitative Systematic Review.

Authors:  Pierluigi Giampaolino; Valeria Cafasso; Dominga Boccia; Mario Ascione; Antonio Mercorio; Francesco Viciglione; Mario Palumbo; Paolo Serafino; Cira Buonfantino; Maria Chiara De Angelis; Paolo Verrazzo; Giovanna Grasso; Giuseppe Gullo; Giuseppe Bifulco; Luigi Della Corte
Journal:  Biomed Res Int       Date:  2022-09-27       Impact factor: 3.246

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.